Cubist Pharmaceuticals Director Martin Rosenberg Sells 15,472 Shares (CBST)
Cubist Pharmaceuticals (NASDAQ:CBST) Director Martin Rosenberg sold 15,472 shares of Cubist Pharmaceuticals stock on the open market in a transaction dated Monday, September 9th. The stock was sold at an average price of $65.00, for a total transaction of $1,005,680.00. Following the sale, the director now directly owns 6,005 shares of the company’s stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on CBST. Analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals (NASDAQ:CBST) in a research note to investors on Monday, August 19th. They now have a $65.00 price target on the stock. Separately, analysts at Aegis upgraded shares of Cubist Pharmaceuticals (NASDAQ:CBST) from a “hold” rating to a “buy” rating in a research note to investors on Thursday, August 1st. They now have a $70.00 price target on the stock, up previously from $56.00. Finally, analysts at Jefferies Group raised their price target on shares of Cubist Pharmaceuticals (NASDAQ:CBST) from $64.00 to $70.00 in a research note to investors on Wednesday, July 31st. They now have a “buy” rating on the stock.
Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Cubist Pharmaceuticals has an average rating of “Buy” and an average price target of $61.92.
Cubist Pharmaceuticals (NASDAQ:CBST) traded up 0.21% on Tuesday, hitting $65.73. 1,081,847 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 1-year low of $38.53 and a 1-year high of $65.77. The stock has a 50-day moving average of $61.51 and a 200-day moving average of $52.0. The company has a market cap of $4.344 billion and a price-to-earnings ratio of 45.33.
Cubist Pharmaceuticals (NASDAQ:CBST) last issued its quarterly earnings data on Thursday, July 18th. The company reported $0.42 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.55 by $0.13. The company had revenue of $258.80 million for the quarter, compared to the consensus estimate of $254.93 million. During the same quarter last year, the company posted $0.68 earnings per share. Cubist Pharmaceuticals’s revenue was up 12.2% compared to the same quarter last year. On average, analysts predict that Cubist Pharmaceuticals will post $1.06 earnings per share for the current fiscal year.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.